FF-10501-01
- Generic Name
- FF-10501-01
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
FF-10501-01 is a novel, selective inosine monophosphate dehydrogenase (IMPDH) inhibitor with anticancer activity. FF-10501-01 is under investigation in clinical trial NCT03486353 (A Study of FF-10501-01 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome).
- Associated Conditions
- -
- Associated Therapies
- -
A Study of FF-10501-01 in Combination with Azacitidine in Patients with Myelodysplastic Syndrome
Phase 2
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2018-04-03
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Fujifilm Pharmaceuticals U.S.A., Inc.
- Registration Number
- NCT03486353
Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies
- First Posted Date
- 2014-07-18
- Last Posted Date
- 2022-04-13
- Lead Sponsor
- Fujifilm Pharmaceuticals U.S.A., Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT02193958
- Locations
- 🇺🇸
Cleveland Clinic at Taussig Cancer Center, Cleveland, Ohio, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath